Study tracks Real-World safety of advanced skin cancer drug for three years

NCT ID NCT04066504

Completed Disease control Sponsor: Sun Pharmaceutical Industries Limited Source: ClinicalTrials.gov ↗

Summary

This study aimed to collect real-world safety information on the drug Odomzo (sonidegib) for patients with advanced basal cell carcinoma who cannot have surgery or radiation. Researchers followed 323 adult patients for up to three years in a routine clinical setting to document side effects and reasons patients might stop treatment. The study did not test a new treatment but observed patients already prescribed the drug by their doctors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AOU Maggiore della Carità - Università del Piemonte Orientale

Novara, Italy
ASL1 Avezzano-Sulmona-L'Aquila

L’Aquila, Italy
ASST Spedali Civili di Brescia

Brescia, Italy
Azienda Toscana Centro - Università di Firenze

Florence, Italy
Complejo Hospitalario Universitario de Pontevedra

Pontevedra, 36001, Spain
Elbe Kliniken Stade - Buxtehude GmbH

Buxtehude, Germany
Fachklinik Muenster-Hornheide

Münster, 48157, Germany
Forndazione I.R.C.C.S. Istituto nazionale dei tumori

Milan, 20133, Italy
Harzklinikum Dorothea Christiane Erxleben GmbH

Quedlinburg, 06484, Germany
Helios Klinikum

Erfurt, 99089, Germany
Helios St. Elisabeth Klinik

Oberhausen, 46045, Germany
Hospital Clínic de Barcelona

Barcelona, 8036, Spain
Hospital General Universitari València

Valencia, 46014, Spain
Hospital Germans Trias i Pujol

Badalona, 8916, Spain
Hospital Universitario La Fe

Valencia, 46026, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Hospital Universitario Nuestra Señora de Candelaria

Santa Cruz de Tenerife, 38010, Spain
Hospital Universitario Ramón y Cajal

Madrid, 28034, Spain
Hospital Universitario de Gran Canaria Doctor Negrín

Las Palmas de Gran Canaria, 35010, Spain
Hospital Vall d'Hebron

Barcelona, 8035, Spain
Hospital de la Santa Creu i Sant Pau

Barcelona, 8041, Spain
I.R.C.C.S Istituto Tumori "Giovanni Paolo II"

Bari, Italy
IDI

Roma, 00167, Italy
Inselspital

Bern, Switzerland
Ist. Scien. Romagnolo per lo Studio e la Cura dei Tumori - IRST

Meldola, 47014, Italy
Istituto Tumori Napoli Fondazione G. Pascale

Naples, 80131, Italy
Johannes Wesling Klinikum Minden

Minden, 32429, Germany
Katholisches Klinikum Bochum St. Josef-Hospital

Bochum, Germany
Klinikum Darmstadt GmbH

Darmstadt, 64297, Germany
Klinikum Ludwigshafen gGmbH

Ludwigshafen, Germany
Klinikum rechts der Isar

München, 80802, Germany
Medizinische Hochschule Hannover

Hanover, '30625, Germany
Ospedale Policlinico San Martino

Genova, 16132, Italy
SRH Wald-Klinikum

Gera, 07548, Germany
Universitaets-Hautklinik Kiel

Kiel, Germany
Universitaetsklinikum Essen

Essen, Germany
Universitaetsklinikum Schleswig-Holstein

Lübeck, Germany
Universitaetsklinikum Tuebingen

Tübingen, Germany
Università Cattolica del Sacro Cuore

Roma, 00168, Italy
Università Degli Studi di Napoli Federico II

Naples, Italy
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden

Dresden, 1307, Germany
Universitätsklinik Magdeburg

Magdeburg, 39120, Germany
Universitätsklinikum Freiburg

Freiburg im Breisgau, 79104, Germany
Universitätsklinikum Hamburg-Eppendorf

Hamburg, 20246, Germany
Universitätsklinikum Regensburg

Regensburg, 93053, Germany
Universitätsklinikum Ulm

Ulm, 89081, Germany
Universitätsspital Zürich

Zurich, CH- 8091, Switzerland

Conditions

Explore the condition pages connected to this study.

BASAL CELL CARCINOMA